Thera-SAbDab

ALSEVALIMAB

>   Structural Summary
TherapeuticAlsevalimab
TargetVTCN1
Heavy ChainQLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS
Light ChainEIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-I
Estimated Status (August '23)Active
Recorded Developmental Technologyna
INN Year Proposed2019
INN Year Recommended2020
Companies InvolvedFive Prime Therapeutics
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy